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A significant proportion of mortality in patients with
chronic hepatitis C with or without cirrhosis is related to
non-hepatic comorbidities such as cardiovascular or psy-
chiatric disease, drug or alcohol use, renal failure, and non-
hepatic cancers [1]. Curing underlying hepatitis C reduces
but does not eliminate the higher rates of liver-related and
all-cause mortality typical of patients with chronic HCV
infection [2, 3]. Although*70% of the observed mortality
reported in large cohorts of patients with chronic hepatitis
C-related cirrhosis can be predicted using liver-specific risk
prediction models such as Child–Turcotte–Pugh (CTP) or
Model for End-Stage Liver Disease (MELD) [4], the
remaining variance largely relates to ‘unpredictable’ (e.g.,
accidents, homicide, suicide) and more ‘predictable’ non-
hepatic morbidities (e.g., heart disease, chronic lung dis-
ease, renal failure, stroke). Optimized systems to predict
the remaining variance could have important implications
for public policy, and if calculable at the point-of-care,
possibly impact shared clinician–patient medical decision-
making.
Previous attempts to predict non-hepatic mortality in
cohorts of patients with liver disease generally have relied
on coding-dependent identification of comorbid illness
from administrative sources [1, 5, 6]. Both the Charlson-
Deyo Index [5] and Cirrhosis Comorbidity Score [1]
identify past medical histories of relevant diseases,
including but not limited to coronary artery disease, kidney
disease, substance abuse disorders, and cancer, using
International Classification of Disease codes from inpatient
and/or outpatient claims data, sources not well suited for
point-of-care decision-making. Furthermore, the magnitude
of improved prediction of all-cause mortality when these
risk models are added to liver-specific prediction models
appears to be relatively modest [6].
The Schonberg Index (SI), developed to predict 5-year
mortality in ambulatory populations age [65 years with
*20 % observed 5-year mortality [7], was subsequently
shown to have strong concordance with 9-year mortality
[9]. The SI includes 11 specific items such as age (per
5 year increments, 65–85), gender, BMI ([25 or B25),
prior diagnosis of any cancer, presence or absence of dia-
betes, smoking history, presence or absence of lung dis-
ease, the number of hospitalizations in the past year, lack of
independence with performance of activities of daily living
(e.g., light housework, preparing meals, shopping, taking
medications, using the telephone, arranging for personal
travel, and managing personal finances), difficulty walking
1/4 mile, and self-reported general health. It can be
administered via questionnaire with minimal clinical
supervision and is easily scored in real time. Higher scores
in the 0–17 range of the index are associated with a higher
mortality. For example, a 75-year-old male in fair health,
with a history of diabetes, with at least one IADL depen-
dency, and difficulty walking 1/4 mile would have a risk
score of 15, predicting a 42 % chance of mortality in
5 years and a 75 % chance of mortality in 9 years [9]. If
evaluation of such a patient in hepatology clinic for con-
sideration of hepatitis C therapy revealed F0-1 fibrosis
based on fibroelastography, could this information be uti-
lized to educate the patient and inform treatment decisions
regarding direct-acting antiviral therapy?
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Natarajan et al. [8] evaluated the accuracy of the SI as a
predictor of non-hepatic mortality in a prospective cohort
of patients evaluated at a single chronic hepatitis C center.
Over a 5 year period, the investigators recruited more than
1000 treatment-naı¨ve hepatitis C-mono-infected adults
during their initial visits to a hepatitis clinic based at a
large Veterans Affairs medical center in order to acquire a
detailed medical history, sociodemographic risk factors,
and laboratory parameters using computer-assisted patient
surveys and chart review. In addition to assessing the SI,
the investigators also collected self-reported histories
regarding cardiovascular disease, alcohol use, and liver
staging estimators (Fibrosure and MELD score) to
determine whether or not these parameters could impact
the predictive capacity of SI. The investigators then used
stepwise Cox proportional hazard models to evaluate the
predictive capacity of models including SI for the outcome
of all-cause mortality. Due to the nature of the recruitment
site, the existing comorbidities and other risk factors for
mortality were widely prevalent among the sampled pop-
ulation. The cohort was overwhelmingly male (97.5 %),
active tobacco users (60 %), only 25 % underweight, and
93 % had at least some significant alcohol use. One-
quarter were diabetic and over half were hypertensive.
Approximately 15 % already had been diagnosed with
cardiovascular disease; a similar fraction had been diag-
nosed with chronic obstructive pulmonary disease; and
17 % had been hospitalized at least once in the prior year.
Only one-quarter reported that walking 1/4 mile would not
pose a difficulty. The mean SI of 8.2 signified a
*13–16 % 5-year mortality risk, a risk estimate inde-
pendent of the risk attributable to cirrhosis, which was
present in one-third of the cohort. In 4.4 years of median
follow-up, the observed mortality rate was actually lower,
only 9.7 %, possibly due to the younger age of the liver
disease cohort than the elderly cohort from which the SI
was derived. The investigators then determined which
variables according to univariate analysis were associated
with mortality. Not surprisingly, the presence of cirrhosis
was the strongest predictor of mortality, with an overall
hazard ratio of 3.3. In multivariable models including
cirrhosis, coronary artery disease, and drug use, each unit
change of SI was associated with a 20 % increase in
mortality.
Strengths of the present study include its sample size,
prospective data collection, and comprehensive collection
of covariates. The work furthers the evidence base for
recognition of the importance of general health and func-
tional status when trying to manage cohorts of patients with
liver disease. It also validates that the SI may be a useful
tool for clinicians to quantify comorbidities for making
liver-related treatment decisions.
The authors indicate that the magnitude of increased risk
associated with 1 point changes in SI is similar to the
magnitude of increased risk associated with 1 point
increases in MELD scores. Nevertheless, unlike MELD,
when grouped into quintiles of SI scores, there was a
notable nonlinearity of increased risk. SI poorly discrimi-
nated differences in mortality risk in non-cirrhotics within
the middle three quintiles of risk. Furthermore, among
cirrhotics, the SI was poorly discriminative for mortality
risks between the 2nd–3rd and 4th–5th quintiles. Thus,
based on these data, the SI cannot be utilized as a linear
variable, but rather must be interpreted as a dichotomized
variable associated with high risk of mortality (e.g.,\11
vs. C11 in non-cirrhotics, or\9 vs. C9 in cirrhotics).
In addition to the nonlinearity of the SI prediction,
several other questions need to be addressed before hepa-
tologists should consider widely applying the SI survey.
First, is it practical outside of an academic environment to
use an 11-variable scale in routine clinical care? The SI can
be self-administered to patients using a roughly 2-page
questionnaire and is fairly simple to score. Yet, routine
administration would incur costs and would require some
type of incentive, such as inclusion as a Center for Medi-
care and Medicaid Service Physician Quality Reporting
System quality indicator for which the present data are not
sufficiently robust. Second, while standardized, does the SI
really provide significantly more information than most
clinicians obtain from a routine history and physical?
Would clinician behavior change if presented with the SI
data during patient care? Such questions need to be
addressed prospectively. Third, would patients at high risk
of non-hepatic mortality be willing to forgo interventions
such as direct-acting antiviral therapy were they presented
with SI-based mortality predictions? How would these data
impact patient–clinician interactions? Again these ques-
tions need to be addressed prospectively.
Application of SI-based risk stratification could theo-
retically positively impact clinical care. Accurate comor-
bidity indices could be used by clinicians to avoid
application of highly costly or risky screening regimens to
patients at high risk of competing mortality. For instance,
when applied to a prostate cancer screening population, the
SI identified retrospectively that 33 % of the screened
population had high risks of mortality and therefore was
unlikely to derive clinical benefit from PSA testing [10]. It
was theorized, but not tested, that educational interventions
could rather have been used by physicians to educate
patients to agree to opt-out, rather than undergo, screening.
Nonetheless, the SI has never been prospectively tested in
such a setting in order to assess its impact on influencing
patient choices. Discussing expected mortality with an
individual could have unpredictable consequences. Thus,
while Natarajan and colleagues should be lauded for taking
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the first steps in the process, much more prospective testing
will be needed before the SI can be considered a routine
component of clinical evaluations in hepatology clinics.
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